Larimar Total Current Liabilities vs Total Liab Analysis

LRMR Stock  USD 7.76  0.09  1.15%   
Larimar Therapeutics financial indicator trend analysis is infinitely more than just investigating Larimar Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Larimar Therapeutics is a good investment. Please check the relationship between Larimar Therapeutics Total Current Liabilities and its Total Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Larimar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.

Total Current Liabilities vs Total Liab

Total Current Liabilities vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Larimar Therapeutics Total Current Liabilities account and Total Liab. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Larimar Therapeutics' Total Current Liabilities and Total Liab is 0.51. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Total Liab in the same time period over historical financial statements of Larimar Therapeutics, assuming nothing else is changed. The correlation between historical values of Larimar Therapeutics' Total Current Liabilities and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Larimar Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Total Current Liabilities i.e., Larimar Therapeutics' Total Current Liabilities and Total Liab go up and down completely randomly.

Correlation Coefficient

0.51
Relationship DirectionPositive 
Relationship StrengthWeak

Total Current Liabilities

Total Current Liabilities is an item on Larimar Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Larimar Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.
Most indicators from Larimar Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Larimar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Larimar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.As of 10/19/2024, Enterprise Value is likely to grow to about 155.7 M, while Selling General Administrative is likely to drop slightly above 8.9 M.
 2023 2024 (projected)
Depreciation And Amortization311K234.5K
Interest Income223.2K365.6K

Larimar Therapeutics fundamental ratios Correlations

-0.040.420.640.99-0.14-0.29-0.380.430.35-0.15-0.191.0-0.210.7-0.250.130.480.431.00.410.420.53-0.12-0.140.52
-0.040.10.09-0.18-0.330.24-0.630.170.03-0.35-0.45-0.02-0.28-0.050.55-0.160.450.81-0.020.760.09-0.38-0.240.450.41
0.420.10.870.370.480.23-0.620.29-0.150.460.280.380.440.41-0.060.290.80.510.390.330.63-0.380.420.36-0.21
0.640.090.870.590.190.17-0.510.66-0.110.15-0.090.610.050.67-0.090.110.740.510.620.40.43-0.050.060.130.1
0.99-0.180.370.59-0.14-0.32-0.270.40.33-0.14-0.160.99-0.20.71-0.30.110.380.290.990.30.380.61-0.11-0.210.48
-0.14-0.330.480.19-0.14-0.140.12-0.310.081.00.78-0.210.66-0.35-0.360.750.12-0.04-0.2-0.420.22-0.620.470.11-0.76
-0.290.240.230.17-0.32-0.14-0.340.24-0.96-0.15-0.15-0.280.280.410.48-0.370.350.06-0.270.240.28-0.360.450.48-0.28
-0.38-0.63-0.62-0.51-0.270.12-0.34-0.160.110.140.2-0.38-0.1-0.37-0.520.07-0.91-0.78-0.38-0.88-0.610.19-0.16-0.72-0.2
0.430.170.290.660.4-0.310.24-0.16-0.21-0.37-0.550.44-0.380.670.05-0.240.330.320.450.37-0.180.19-0.34-0.090.35
0.350.03-0.15-0.110.330.08-0.960.11-0.210.080.080.34-0.29-0.39-0.360.37-0.180.20.340.0-0.190.27-0.46-0.340.4
-0.15-0.350.460.15-0.141.0-0.150.14-0.370.080.82-0.220.68-0.36-0.40.740.08-0.07-0.21-0.460.26-0.60.510.07-0.75
-0.19-0.450.28-0.09-0.160.78-0.150.2-0.550.080.82-0.240.86-0.39-0.60.51-0.15-0.24-0.24-0.60.35-0.410.74-0.13-0.6
1.0-0.020.380.610.99-0.21-0.28-0.380.440.34-0.22-0.24-0.250.72-0.220.060.460.421.00.430.40.58-0.15-0.140.57
-0.21-0.280.440.05-0.20.660.28-0.1-0.38-0.290.680.86-0.25-0.15-0.320.440.13-0.11-0.25-0.340.54-0.50.940.18-0.65
0.7-0.050.410.670.71-0.350.41-0.370.67-0.39-0.36-0.390.72-0.150.05-0.280.50.230.720.40.40.420.070.030.33
-0.250.55-0.06-0.09-0.3-0.360.48-0.520.05-0.36-0.4-0.6-0.22-0.320.05-0.370.430.25-0.220.67-0.13-0.17-0.270.82-0.05
0.13-0.160.290.110.110.75-0.370.07-0.240.370.740.510.060.44-0.28-0.370.080.130.07-0.230.2-0.350.290.01-0.4
0.480.450.80.740.380.120.35-0.910.33-0.180.08-0.150.460.130.50.430.080.740.470.780.6-0.250.160.70.01
0.430.810.510.510.29-0.040.06-0.780.320.2-0.07-0.240.42-0.110.230.250.130.740.430.790.41-0.3-0.10.380.4
1.0-0.020.390.620.99-0.2-0.27-0.380.450.34-0.21-0.241.0-0.250.72-0.220.070.470.430.430.40.57-0.15-0.140.56
0.410.760.330.40.3-0.420.24-0.880.370.0-0.46-0.60.43-0.340.40.67-0.230.780.790.430.260.01-0.270.640.45
0.420.090.630.430.380.220.28-0.61-0.18-0.190.260.350.40.540.4-0.130.20.60.410.40.26-0.120.670.240.0
0.53-0.38-0.38-0.050.61-0.62-0.360.190.190.27-0.6-0.410.58-0.50.42-0.17-0.35-0.25-0.30.570.01-0.12-0.4-0.450.6
-0.12-0.240.420.06-0.110.470.45-0.16-0.34-0.460.510.74-0.150.940.07-0.270.290.16-0.1-0.15-0.270.67-0.40.17-0.53
-0.140.450.360.13-0.210.110.48-0.72-0.09-0.340.07-0.13-0.140.180.030.820.010.70.38-0.140.640.24-0.450.17-0.37
0.520.41-0.210.10.48-0.76-0.28-0.20.350.4-0.75-0.60.57-0.650.33-0.05-0.40.010.40.560.450.00.6-0.53-0.37
Click cells to compare fundamentals

Larimar Therapeutics Account Relationship Matchups

Larimar Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets5.2M104.7M78.7M126.4M95.9M86.1M
Short Long Term Debt Total8.6M6.5M6.0M5.4M5.5M7.2M
Other Current Liab2.3M5.8M6.6M8.4M7.4M6.9M
Total Current Liabilities5.9M9.0M8.8M10.7M9.5M7.8M
Total Stockholder Equity(694K)89.7M64.4M110.9M81.7M73.0M
Property Plant And Equipment Net361K5.0M4.5M3.7M3.8M2.2M
Net Debt(912K)(61.6M)(64.1M)(21.4M)(21.2M)(22.3M)
Retained Earnings(23.1M)(65.6M)(116.3M)(151.6M)(188.6M)(198.0M)
Accounts Payable3.5M2.6M1.7M1.7M1.3M2.4M
Cash1.0M68.1M70.1M26.8M26.7M32.7M
Non Current Assets Total451K6.7M6.5M5.7M5.8M3.1M
Non Currrent Assets Other90K419K669K638K659K692.0K
Cash And Short Term Investments1.0M92.6M70.1M118.4M86.8M81.5M
Common Stock Shares Outstanding3.1M11.9M17.2M25.8M43.9M46.1M
Short Term Investments43.1M24.5M0.091.6M60.0M52.2M
Liabilities And Stockholders Equity5.2M104.7M78.7M126.4M95.9M86.1M
Non Current Liabilities Total14.9M6.0M5.4M4.8M4.7M7.2M
Other Current Assets419K5.3M2.1M2.3M3.4M2.4M
Other Stockholder Equity22.4M155.3M180.6M262.5M270.2M200.3M
Total Liab5.9M15.0M14.3M15.5M14.2M13.1M
Total Current Assets4.8M98.0M72.2M120.7M90.2M83.9M
Accumulated Other Comprehensive Income35K1K0.0(31K)81K85.1K
Short Term Debt97K515K594K611K837K1.4M
Common Stock6K15K18K43K49.5K29.3K
Other Assets26K90K0.02.0M2.3M2.4M
Net Receivables1.5M158K32K208K187.2K177.8K
Capital Surpluse444.2M449.9M155.3M262.5M236.2M272.9M
Property Plant And Equipment Gross7.9M5.0M4.5M3.7M5.0M3.5M
Property Plant Equipment361K5.0M4.5M831K955.7K1.8M
Net Tangible Assets(694K)89.7M64.4M110.9M127.5M133.9M

Pair Trading with Larimar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Larimar Stock

  0.63VALN Valneva SE ADRPairCorr
  0.77DYAI Dyadic InternationalPairCorr
  0.76ERNA Eterna TherapeuticsPairCorr

Moving against Larimar Stock

  0.67GILD Gilead SciencesPairCorr
  0.66BMY Bristol Myers SquibbPairCorr
  0.65A Agilent Technologies Fiscal Year End 18th of November 2024 PairCorr
  0.46JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.45GNFT GenfitPairCorr
The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.
The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Larimar Stock Analysis

When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.